• Abivax priced a follow-on offering of 6,400,000 ADSs at USD 125 per ADS.
• Net proceeds expected at about USD 759.8 million, or EUR 666.8 million, after underwriting discounts and estimated offering costs.
• Offering expected to close July 6, 2026, subject to customary closing conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abivax SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-294514), on July 02, 2026, and is solely responsible for the information contained therein.